Teva Pharmaceutical Industries Ltd (TEVA)

The devastation of the coronavirus was the last straw for the Trump administration, prompting an aggressive approach to U.S.-China relations. Here are some of the top companies to invest in to account for this foreign policy shift.

8 Cheap Stocks to Keep on Your Short List

By Josh Enomoto, InvestorPlace Contributor Aug 13, 2020

Due to the disjointed fundamentals, many investors were caught off guard with this current bull market. However, there are cheap stocks to buy that are still available.

10 Stocks to Buy for Your 10-Year-Old

By Josh Enomoto, InvestorPlace Contributor Aug 7, 2020

With digitalization trends changing how we live and work, these ten stocks to buy are perfect for your long-term portfolio – or your young children’s.

9 Healthcare Stocks to Buy Even After the Coronavirus Fades

By Josh Enomoto, InvestorPlace Contributor Apr 28, 2020

Several healthcare stocks have jumped higher based off the coronavirus pandemic. But these nine companies have a longer upside pathway.

9 Recession-Proof Stocks to Disinfect the Coronavirus

By Josh Enomoto, InvestorPlace Contributor Mar 10, 2020

As the coronavirus pandemic worsens, stable but boring recession-proof stocks to buy are suddenly in vogue. Here are the nine picks that might ride this black swan even to profitability.

Teva Stock Was a Good Buy Last Fall, but It Topped out After This Rally

By Thomas Niel Feb 27, 2020

TEVA stock was a great contrarian play last fall. With opioid liabilities hanging like an anvil over the company, shares were priced for disaster. More than doubling from their 2019 lows, I wouldn't say Teva shares are now "priced to perfection". But, the current share price may be pricing in much of the upside. Bottom Line? Consider TEVA stock a hold. With markets facing volatility, a better entry point could spring up down the road.

Potholes Remain for Teva Pharmaceutical Stock

By Vince Martin, InvestorPlace Contributor Feb 26, 2020

TEVA stock has rallied as its business has stabilized. But even with shares still cheap, investors shouldn't ignore the myriad risks.

Now That Teva Has Stabilized, Teva Stock Looks Undervalued

By Larry Ramer, InvestorPlace Contributor Feb 25, 2020

The forward price-earnings ratio of Teva stock is only 5, and its trailing price/sales ratio is 0.8. With Teva's financial situation in control and given the company's multiple growth drivers, those valuation metrics are quite low.

Opioids Made TEVA Stock Untouchable But Things Seem to be Changing

By Josh Enomoto, InvestorPlace Contributor Feb 19, 2020

TEVA stock is about as far from a feel-good investment as you can get. But the underlying generics drug industry is still an important one, making shares a tough contrarian opportunity.

Positive Earnings Look as If They’re Already Priced in to Teva Stock

By Chris Markoch Feb 14, 2020

Teva stock rose 9% after a positive earnings report. But after $3 billion in cost-cutting, investors may be looking for additional revenue.

15 Stocks to Buy Based On The 2020 U.S. Presidential Election

By Luke Lango, InvestorPlace Senior Investment Analyst Feb 13, 2020

Here's your complete guide on which stocks to buy, depending on who wins the 2020 U.S. Presidential Election.

3 Reasons Why Beaten-Up Teva Stock Could Have a Big 2020

By Luke Lango, InvestorPlace Senior Investment Analyst Feb 13, 2020

It increasingly appears that Teva stock is in the early stages of going from multi-year loser to multi-year winner.

Teva Pharmaceuticals Earnings: TEVA Stock Takes 10% Jump on Q4 Beat

By William White, InvestorPlace Writer Feb 12, 2020

Teva Pharmaceuticals (TEVA) earnings for the pharmaceutical company's fourth quarter of 2019 have TEVA stock taking off on Wednesday.

10 Strong Lottery Ticket Stocks That Could Soar in 2020

By Luke Lango, InvestorPlace Senior Investment Analyst Feb 12, 2020

Looking for a stock that will double or triple in 2020? These 10 lottery stocks have a realistic opportunity to do just that.

Teva Pharmaceutical Just Got a Little Migraine Relief

By Will Ashworth, InvestorPlace Contributor Feb 4, 2020

With plans to capture 25% of the market, the nod from the FDA should help reduce the sting of having to abandon its planned use of Ajovy for cluster headaches, a move that was dropped last year after a failed phase 3 trial, which gave Eli Lilly the market to itself.